GlassScriptPhysician profile
Stephanie Ross
NPI 1356885313
$7,077.01
in general payments reported to CMS, 2019-2025
28 companies · $1,571 in 2025
The $1,571 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $840 · 2021: $803 · 2022: $1,170 · 2023: $551 · 2024: $1,347 · 2025: $1,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,410 · Entertainment: $59.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,409.50 |
| Entertainment | $59.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,195.63 | 2019-2025 | Acuvue |
| Coopervision INC. | $1,190.71 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $1,007.36 | 2019-2025 | Total30, Precision7, Rocklatan |
| Bausch & Lomb Americas INC. | $681.39 | 2022-2025 | Miebo, Infuse, Xiidra |
| Tarsus Pharmaceuticals, INC. | $506.66 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $504.02 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $287.86 | 2020-2023 | |
| Sun Pharmaceutical Industries INC. | $234.72 | 2022-2025 | |
| Oyster Point Pharma, INC. | $212.54 | 2022-2025 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Surgical Vision, INC. | $206.28 | 2019-2025 | Tecnis Iol |
| Rxsight INC | $137.56 | 2023 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal) |
| Abb Con-Cise Optical Group LLC | $135.11 | 2019-2025 | Contact Lens, Spectacle Lenses |
| Glaxosmithkline, LLC. | $124.99 | 2022 | |
| Aerie Pharmaceuticals, INC. | $111.35 | 2019 | |
| Biotissue Holdings INC. | $99.76 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $98.28 | 2021-2022 | |
| Ivantis, INC | $88.23 | 2020 | |
| Optos, INC. | $59.50 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Harrow Eye, LLC | $37.58 | 2025 | Vevye |
| Shire North American Group INC | $30.23 | 2019 | |
| Abbvie INC. | $28.01 | 2022 | |
| Allergan, INC. | $22.87 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.60 | 2023 | Cyltezo |
| Carl Zeiss Meditec USA, INC. | $18.13 | 2025 | Cirrus Hd-Oct |
| Kala Pharmaceuticals, INC. | $14.27 | 2021 | |
| Lkc Technologies, INC. | $13.84 | 2023 | |
| Eyevance Pharmaceuticals LLC | $11.53 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.